https://doi.org/10.4081/monaldi.2018.961
Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation
Accepted: May 11, 2018
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Old age remains one of the strongest risk factors for stroke in patients with atrial fibrillation (AF). Oral anticoagulation (OAC) is the most effective way to prevent thromboembolic disease in patients with atrial fibrillation (AF). Until few years ago, aspirin and vitamin-K antagonists (VKAs) were the primary agents used to prevent thromboembolic disease in patients with AF. The approval of non–vitamin K oral anticoagulants (NOACs) has now expanded the range of therapeutic agents available to providers. The authors highlight practical considerations regarding the selection and use of OAC in older adults to aid clinical decision making.
How to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Maria Teresa La Rovere, Egidio Traversi, Prognostic impact of digoxin use for rate control of atrial fibrillation in patients ≥75 years of age , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- Francesco Orso, Riccardo Barucci, Stefania Fracchia, Giulio Mannarino, Alessandra Pratesi, Francesco Fattirolli, Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by New Oral Anticoagulants, to be cautiously used , Monaldi Archives for Chest Disease: Vol. 80 No. 4 (2013): Cardiac Series
- Giovanni Luca Botto, Carlo Piemontese, Giovanni Russo, Rhythm-control vs rate-control in the elderly: When to do it and which drug to prefer? , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- Stefania Angela Di Fusco, Furio Colivicchi, Nadia Aspromonte, Marco Tubaro, Alessandro Aiello, Massimo Santini, Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials , Monaldi Archives for Chest Disease: Vol. 87 No. 1 (2017)
- Maurizio Giuseppe Abrignani, Furio Colivicchi, Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part I: the thromboembolic risk , Monaldi Archives for Chest Disease: Vol. 80 No. 2 (2013): Cardiac series
- Mario Sorice, Francesco Paolo Tritto, Chiara Sordelli, Rosario Gregorio, Luigi Piazza, N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing “on-pump†coronary artery bypass graft surgery , Monaldi Archives for Chest Disease: Vol. 76 No. 2 (2011): Cardiac series
- Niccolò Marchionni, Francesco Orso, Cholesterol: until which age 'the lower the better'? , Monaldi Archives for Chest Disease: Vol. 84 No. 1-2 (2015): Cardiac series
- Maurizio Giuseppe Abrignani, Vincenzo Abrignani, Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part II: hemorrhagic risk and guidelines recommendations , Monaldi Archives for Chest Disease: Vol. 80 No. 3 (2013): Cardiac series
- Stefano Fumagalli, Serena Boni, Simone Pupo, Marta Migliorini, Irene Marozzi, Eleonora Barghini, Flavia Sacco, Niccolò Marchionni, Rate-control vs rhythm-control of atrial fibrillation in elderly patients. From new, age-oriented outcomes to a more complex management strategy , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
- Giuseppe Patti, Ludmilla Mantione, Edoardo Bressi, Antonio Bisignani, Efficacy and safety of oral anticoagulant therapy in frail patients with atrial fibrillation , Monaldi Archives for Chest Disease: Vol. 88 No. 2 (2018)
You may also start an advanced similarity search for this article.
